Prospect: information for the user
REZOLSTA 800 mg/150 mg - film-coated tablets
darunavir/cobicistat
Read the entire prospectus carefully before starting to take this medication, as it contains important information for you.
Contents of the prospectus
What is REZOLSTA?
REZOLSTA contains the active ingredients darunavir and cobicistat.
Darunavir belongs to a group of HIV medications called "protease inhibitors", which reduce the amount of HIV in your body to a very low level. Darunavir is administered with cobicistat, which increases the amount of darunavir in your blood.
Treatment with REZOLSTA will improve your immune system (your body's natural defenses) and reduce the risk of suffering from diseases related to HIV infection, although REZOLSTA is not a cure for HIV infection.
What is it used for?
REZOLSTA is used to treat adults and adolescents from 12 years of age who weigh at least 40 kilograms and are infected with HIV (see How to take REZOLSTA).
REZOLSTA should be taken in combination with other HIV medications. Your doctor will explain the most suitable combination of medications for you.
Do not take REZOLSTA
Do not combine REZOLSTA with any of the following medications
If you are taking any of these medications, consult your doctor to change to another medication.
Medication | Purpose of the medication |
Alfuzosin | to treat prostate enlargement (hyperplasia) |
Amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine | to treat certain heart disorders, such as arrhythmias |
Carbamazepine, phenobarbital, and phenytoin | to prevent seizures |
Astemizole or terfenadine | to treat allergy symptoms |
Colchicine(if you have kidney or liver problems) | to treat gout or familial Mediterranean fever |
The combination of medications lopinavir/ritonavir | HIV medication |
Rifampicin | to treat certain infections, such as tuberculosis |
Lurasidone, pimozide, quetiapine, or sertindole | to treat psychiatric disorders |
Ergot alkaloids such as ergotamine, dihydroergotamine, ergometrine, and methylergonovine | to treat migraines |
Cisapride | to treat certain stomach problems |
St. John's Wort (Hypericum perforatum) | herbal medicine used for depression |
Elbasvir/grazoprevir | to treat hepatitis C infection |
Lovastatin, simvastatin, and lomitapide | to reduce cholesterol levels |
Triazolam or oral midazolam(taken by mouth) | to help you sleep and/or relieve anxiety |
Sildenafil | to treat a heart and lung disorder called pulmonary arterial hypertension. Sildenafil has other indications. See the section Other medications and REZOLSTA. |
Avanafil | to treat erectile dysfunction |
Dabigatran, ticagrelor | to help stop platelet aggregation in the treatment of patients with a history of heart attack |
Naloxegol | to treat opioid-induced constipation |
Dapoxetine | to treat premature ejaculation |
Domperidone | to treat nausea and vomiting |
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take REZOLSTA.
When receiving this medication, you can still transmit HIV, although the risk is reduced with effective antiretroviral treatment. Consult your doctor about the necessary precautions to avoid infecting others.
People taking REZOLSTA may contract infections and other diseases associated with HIV infection. You should maintain regular contact with your doctor.
People taking REZOLSTA may develop a skin rash. In rare cases, a rash can become severe or potentially life-threatening. Please consult your doctor if you experience a rash.
In patients treated with REZOLSTA and raltegravir (for HIV infection), skin rashes (usually mild or moderate) may occur more frequently than in patients taking either of these medications separately.
REZOLSTA has been used in a limited number of patients aged 65 or older. If you belong to this age group, talk to your doctor before taking REZOLSTA.
Check the following points and inform your doctor if you are in any of these situations.
Children and adolescents
REZOLSTA should not be used in children under 12 years of age or weighing less than 40 kilograms.
Taking REZOLSTA with other medications
Tell your doctor or pharmacist if you are using or have recently used other medications.
Some other medications should not be combinedwith REZOLSTA. These medications are listed below in the section "Do not combine REZOLSTA with any of the following medications:"
REZOLSTA should not be used with any other antiviral medication that contains a booster or another antiviral that requires a booster. In some cases, the dose of other medications may need to be adjusted. Therefore, always inform your doctor if you are taking other HIV medications and follow their instructions strictly regarding which medications can be combined.
The effects of REZOLSTA may be reduced if you take any of the following medications. Inform your doctor if you take:
REZOLSTA may also affect the effects of other medications. Inform your doctor if you take:
It may be necessary to adjust the dosage of other medications if their therapeutic or adverse effects or those of REZOLSTA are affected when administered together. Inform your doctor if you take:
This is nota complete list of medications. Inform your doctor of allthe medications you are taking.
Pregnancy and breastfeeding
Inform your doctor immediately if you are pregnant, plan to become pregnant, or are breastfeeding. Pregnant or breastfeeding women should not take REZOLSTA. It is recommended that HIV-infected women do not breastfeed their child, both due to the possibility of transmitting the infection through breast milk and the unknown effects of this medication on the child.
Driving and using machines
Do not operate machinery or drive if you experience dizziness after taking REZOLSTA.
Follow the administration instructions of this medication exactly as indicated by your doctor, pharmacist, or nurse. In case of doubt, consult your doctor, pharmacist, or nurse again.
You must take REZOLSTA daily and always with food. REZOLSTA cannot work properly without food. You must take a meal or snack within 30 minutes before taking REZOLSTA. The type of food is not important.
Removing the child-resistant cap
The plastic bottle has a child-resistant cap and is opened as follows:
|
If you take more REZOLSTA than you should
Inform your doctor, pharmacist, or nurse immediately.
If you forget to take REZOLSTA
If you realize within 12 hoursafterwards, take the tablet immediately. Always take it with food. If you realize after 12 hours, skip that dose and take the next dose as usual. Do not take a double dose to make up for the forgotten dose.
If you vomit after taking REZOLSTA
If you vomit less than 4 hoursafter taking the medication, you must take another dose of REZOLSTA with food as soon as possible. If you vomit when more than 4 hourshave passed since you took the medication, it is not necessary to take another dose of REZOLSTA until the next scheduled administration time.
Contact your doctor if you have doubtsabout what to do if you forget a dose or vomit.
Do not stop taking REZOLSTA without talking to your doctor
Once treatment is started, it should not be suspended without the doctor's instructions.
HIV medications can make you feel better. Even if you feel better, do not stop taking REZOLSTA. Consult your doctor first.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can cause side effects, although not all people experience them.
Tell your doctor if you experience any of the following side effects.
Liver problems have been described, which can occasionally be serious. Your doctor should perform blood tests before you start treatment with REZOLSTA. If you have chronic hepatitis B or C infection, your doctor should repeat blood tests more frequently, as you may have a higher risk of liver problems. Talk to your doctor about the signs and symptoms of liver problems. They may include yellowing of the skin or the whites of the eyes, dark-colored urine (like dark tea), pale-colored stools (bowel movements), nausea, vomiting, loss of appetite, or pain, discomfort, or pain and discomfort in the right side below the ribs.
A common side effect of REZOLSTA is skin rash (more frequent when used in combination with raltegravir), itching. The rash is usually mild or moderate. The skin rash can also be a symptom of a rare, serious disorder. Therefore, it is essential to talk to your doctor if you develop a rash. Your doctor will indicate how to act on your symptoms and whether you should stop taking REZOLSTA.
Other serious side effects, seen in up to 1 patient in 10, were diabetes. Pancreatitis (inflammation of the pancreas) has been reported in up to 1 patient in 100.
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Side effects with unknown frequency: a rash can become severe or potentially life-threatening:
Some side effects are typical of HIV medications that belong to the same family as REZOLSTA. These are:
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are possible side effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the carton and on the bottle after EXP. The expiration date is the last day of the month indicated.
Do not use this medication after 6 weeks after the first opening of the bottle.
REZOLSTA does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of REZOLSTA
Appearance and package contents
Film-coated tablet, pink, oval, engraved with TG on one side, 800 on the other. 30 tablets in a plastic bottle.
Marketing authorization holderJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Manufacturer
Janssen-Cilag SpA, Via C. Janssen, Borgo San Michele, 04100 Latina, Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 janssen@jacbe.jnj.com | Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 lt@its.jnj.com |
???????? „??????? & ??????? ????????” ???? ???.: +359 2 489 94 00 jjsafety@its.jnj.com | Luxembourg/Luxemburg Janssen-Cilag NV Tél/Tel: +32 14 64 94 11 janssen@jacbe.jnj.com |
Ceská republika Janssen-Cilag s.r.o. Tel: +420 227 012 227 | Magyarország Janssen-Cilag Kft. Tel.: +36 1 884 2858 janssenhu@its.jnj.com |
Danmark Janssen-Cilag A/S Tlf: +45 4594 8282 jacdk@its.jnj.com | Malta AM MANGION LTD Tel: +356 2397 6000 |
Deutschland Janssen-Cilag GmbH Tel: +49 2137 955 955 jancil@its.jnj.com | Nederland Janssen-Cilag B.V. Tel: +31 76 711 1111 janssen@jacnl.jnj.com |
Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 7410 ee@its.jnj.com | Norge Janssen-Cilag AS Tlf: +47 24 12 65 00 jacno@its.jnj.com |
Ελλ?δα Janssen-Cilag Φαρμακευτικ? Α.Ε.Β.Ε. Tηλ: +30 210 80 90 000 | Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
España Janssen-Cilag, S.A. Tel: +34 91 722 81 00 contacto@its.jnj.com | Polska Janssen-Cilag Polska Sp. z o.o. Tel.: +48 22 237 60 00 |
France Janssen-Cilag Tél: 0 800 25 50 75 / +33 1 55 00 40 03 medisource@its.jnj.com | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 jjsafety@JNJCR.JNJ.com | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 Janssen_safety_slo@its.jnj.com |
Ísland Janssen-Cilag AB c/o Vistor hf. Sími: +354 535 7000 janssen@vistor.is | Slovenská republika Johnson & Johnson, s.r.o. Tel: +421 232 408 400 |
Italia Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com | Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 300 jacfi@its.jnj.com |
Κ?προς Βαρν?βας Χατζηπαναγ?ς Λτδ Τηλ: +357 22 207 700 | Sverige Janssen-Cilag AB Tfn: +46 8 626 50 00 jacse@its.jnj.com |
Latvija UAB "JOHNSON & JOHNSON" filiale Latvija Tel: +371 678 93561 lv@its.jnj.com | United Kingdom Janssen-Cilag Ltd. Tel: +44 1 494 567 444 |
Date of last revision of this leaflet: {MM/AAAA}.
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.